Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | DGAT1 | O75907 | 6/20 | 0.54 |
| ▸ | CSGALNACT1 | Q8TDX6 | 11/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1756291 | 1.00 | MEN1 (0.56) | MEN1KMT2AALDH1A1DGAT1CSGALNACT1 | |
| SCHEMBL1756245 | 0.90 | CSGALNACT1 (0.67) | MEN1KMT2AALDH1A1DGAT1CSGALNACT1 | |
| SCHEMBL1756242 | 0.90 | CSGALNACT1 (0.67) | MEN1KMT2AALDH1A1DGAT1CSGALNACT1 | |
| SCHEMBL1756202 | 0.90 | MEN1 (0.52) | MEN1KMT2AALDH1A1DGAT1CSGALNACT1 | |
| SCHEMBL11969065 | 0.90 | MEN1 (0.52) | MEN1KMT2AALDH1A1DGAT1CSGALNACT1 | |
| SCHEMBL1756310 | 0.89 | CSGALNACT1 (0.69) | DGAT1CSGALNACT1 | |
| SCHEMBL1756269 | 0.89 | CSGALNACT1 (0.69) | DGAT1CSGALNACT1 | |
| SCHEMBL1756360 | 0.88 | DGAT1 (0.71) | MEN1KMT2AALDH1A1DGAT1CSGALNACT1 | |
| SCHEMBL1756306 | 0.87 | CSGALNACT1 (0.65) | DGAT1CSGALNACT1 | |
| SCHEMBL1756250 | 0.87 | DGAT1 (0.69) | DGAT1CSGALNACT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8722901-B2 | Carboxy oxazole or thiazole compounds as DGAT-1 inhibitors useful for the treatment of obesity | Piramal Enterprises Limited (IN) | 2014-05-13 | — | — | US | claimed |
| EP-2496564-A2 | HETEROARYL COMPOUNDS AS DGAT-1 INHIBITORS | Piramal Life Sciences Limited (IN) | 2012-09-12 | — | — | EP | claimed |
| US-20120214854-A1 | CARBOXY OXAZOLE OR THIAZOLE COMPOUNDS AS DGAT- 1 INHIBITORS USEFUL FOR THE TREATMENT OF OBESITY | Piramal Enterprises Limited (IN) | 2012-08-23 | — | — | US | claimed |
| WO-2011055289-A2 | HETEROARYL COMPOUNDS AS DGAT-1 INHIBITORS | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2011-05-12 | — | — | WO | claimed |
| US-8722901-B2 | Carboxy oxazole or thiazole compounds as DGAT-1 inhibitors useful for the treatment of obesity | Piramal Enterprises Limited (IN) | 2014-05-13 | — | — | US | disclosed |
| EP-2496564-A2 | HETEROARYL COMPOUNDS AS DGAT-1 INHIBITORS | Piramal Life Sciences Limited (IN) | 2012-09-12 | — | — | EP | disclosed |
| US-20120214854-A1 | CARBOXY OXAZOLE OR THIAZOLE COMPOUNDS AS DGAT- 1 INHIBITORS USEFUL FOR THE TREATMENT OF OBESITY | Piramal Enterprises Limited (IN) | 2012-08-23 | — | — | US | disclosed |
| WO-2011055289-A2 | HETEROARYL COMPOUNDS AS DGAT-1 INHIBITORS | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2011-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214854-A1 | CARBOXY OXAZOLE OR THIAZOLE COMPOUNDS AS DGAT- 1 INHIBITORS USEFUL FOR THE TREATMENT OF OBESITY | DGAT1, DGAT2, DLAT | MEN1 4316/4885KMT2A 1931/4885ALDH1A1 592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.